Tumor antigen presentation to adaptive immune system

Tumor antigen presentation to the adaptive immune system refers to the process wherein tumor-derived peptides are processed by antigen-presenting cells, such as dendritic cells and macrophages, and displayed on their surface bound to MHC molecules. This antigen–MHC complex is recognized by T cell receptors on CD4+ or CD8+ T cells, triggering a targeted immune response against the tumor. Effective antigen presentation is fundamental to cancer immunosurveillance and is the basis for modern immunotherapies, such as immune checkpoint inhibitors and personalized cancer vaccines. Tumors may evade immune destruction by impairing antigen presentation pathways, downregulating MHC molecules, or creating an immunosuppressive microenvironment, presenting major challenges for therapeutic intervention[1][2][3][4][6]. Since this entry refers to a pathway rather than a singular, targetable molecular entity, it is not considered a canonical or druggable target. If structured drug target data is needed, consider extracting individual proteins—such as MHC Class I, dendritic cell receptor, or immune checkpoint molecules (PD-1, CTLA-4)—which are defined targets within this pathway.

Other names

Antigen processing and presentation in cancerTumor antigen cross-presentationImmune surveillance via antigen presentation

Enhancement of antigen presentation (especially MHC-I/II); Inhibition of immune checkpoints (PD-1/PD-L1, CTLA-4); Activation of T cell response against tumor antigens